You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

noncutaneous extranodal lymphoma

Showing 1 - 25 of 5,386
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

Active, not recruiting
  • Adult Lymphocyte Depletion Hodgkin Lymphoma
  • +16 more
  • 6,8-bis(benzylthio)octanoic acid
  • bendamustine hydrochloride
  • Winston-Salem, North Carolina
  • +1 more
Apr 8, 2022

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

NK-T-Cell Lymphoma, Extranodal Trial (Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
  • (no location specified)
Mar 7, 2023

Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Low-Dose Decitabine plus anti-PD-1
  • Beijing, Beijing, China
    ChinaPLAGH
Apr 18, 2023

Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma

Terminated
Has Results
  • Adult Grade III Lymphomatoid Granulomatosis
  • +116 more
  • brentuximab vedotin
  • +2 more
  • Chicago, Illinois
  • +2 more
Aug 30, 2021

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +35 more
  • Akt inhibitor MK2206
  • laboratory biomarker analysis
  • Houston, Texas
    M D Anderson Cancer Center
Oct 14, 2020

Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

Not yet recruiting
  • Advanced Diffuse Large B-Cell Lymphoma
  • +2 more
  • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
  • Radiotherapy beyond standard R-CHOP Chemotherapy
  • (no location specified)
May 24, 2023

Extranodal NK/T Cell Lymphoma, Nasal Type Trial in Guangdong (IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody))

Active, not recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 10, 2022

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • (no location specified)
Jul 28, 2022

Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Not yet recruiting
  • Lymphoma
  • +8 more
  • No interventions need to be specified for this study
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 15, 2023

Lymphoma Trial in Milan (clarithromycin, oral, high dose)

Completed
  • Lymphoma
  • clarithromycin, oral, high dose
  • Milan, Italy
    Dpt of OncoHematology - Fondazione Centro San Raffaele del Monte
Aug 10, 2022

Extranodal Natural Killer T Cell Lymphoma Trial in China (Tislelizumab combined with Liposomal mitoxantrone HCl, Maintenance of

Recruiting
  • Extranodal Natural Killer T Cell Lymphoma
  • Tislelizumab combined with Liposomal mitoxantrone hydrochloride
  • Maintenance of tislelizumab
  • Beijing, China
  • +5 more
Jul 15, 2022

Extranodal NK/T-cell Lymphoma Trial in Bangkok (B-MAD chemo)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma
  • B-MAD chemotherapy
  • Bangkok, Thailand
    King Chulalongkorn Memorial Hospital
May 7, 2022

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Extranodal NK/T Cell Lymphoma Trial in Nanjing (Pegaspargase(P-GOD), Pegaspargase(PEMD))

Not yet recruiting
  • Extranodal NK/T Cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 16, 2022

Primary Extranodal Lymphoma, DLBCL Trial (Camrelizumab)

Not yet recruiting
  • Primary Extranodal Lymphoma
  • DLBCL
  • (no location specified)
Apr 6, 2022

Extranodal Natural Killer/T-cell Lymphoma Trial in Nanjing (circulate free methylated EBV DNA)

Not yet recruiting
  • Extranodal Natural Killer/T-cell Lymphoma
  • circulate free methylated EBV DNA
  • Nanjing, China
    The First Affiliated Hospital of Nanjing Medical University
Apr 19, 2022

Extranodal NK/T-cell Lymphoma Trial in Houston (sugemalimab)

Available
  • Extranodal NK/T-cell Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Mar 18, 2022

Extranodal NK/T-cell Lymphoma Trial in Korea, Republic of (VT-EBV-N, Placebo)

Recruiting
  • Extranodal NK/T-cell Lymphoma
  • VT-EBV-N
  • Placebo
  • Busan, Korea, Republic of
  • +7 more
Apr 28, 2022

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Lymphoma, Extranodal NK-T-Cell Trial in Seoul (avelumab)

Active, not recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Seoul, Korea, Republic of
    81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Sep 22, 2021

Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Beijing (Anti-PD-1 mAb)

Recruiting
  • Early-stage
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Dec 7, 2021

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 6, 2022